An interventional study of Clamping and restauration of arterial blood of the inferior mesenteric artery in Rectal Cancer, Colon Cancer and Ovarian Cancer, sponsored by Institut du Cancer de Montpellier - Val d'Aurelle. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-14.
Sponsored by Institut du Cancer de Montpellier - Val d'Aurelle · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Rectal Neoplasms by Institut du Cancer de Montpellier - Val d'Aurelle — 4 open to participants now, 6 under way, 1 of them phase 3. Rectal Neoplasms · Institut du Cancer de Montpellier - Val d'Aurelle.
Among the 12 studies in Rectal Neoplasms by Institut du Cancer de Montpellier - Val d'Aurelle, this one is the 8th largest by planned enrollment of the 10 interventional ones that give a count, is the only one that started in 2025, is one of 6 with no phase, and was the 11th registered.
2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.
Browse Rectal Neoplasms studies →4 of the 12 studies in Rectal Neoplasms by Institut du Cancer de Montpellier - Val d'Aurelle are open now, in 1 country. Recruiting first, the newest first:
Institut du Cancer de Montpellier - Val d'Aurelle · Sites in France
Ages 18+
Institut du Cancer de Montpellier - Val d'Aurelle · Sites in France
Ages 18+
Institut du Cancer de Montpellier - Val d'Aurelle · Sites in France
Ages 18+
By country, each count listing its studies:
Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 2
First in 2001; this study’s year is marked. 1 started in 2025.
This study's planned enrollment of 50 is below the median of 65 across 1,754 interventional studies indexed under Rectal Neoplasms.
Median enrollment 184 across the 10 interventional studies, 607 across the 2 observational. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Institut du Cancer de Montpellier - Val d'Aurelle is the lead sponsor of 142 studies on the registry; 46 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Rectal Neoplasms by Institut du Cancer de Montpellier - Val d'Aurelle, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Colorectal cancers and ovarian cancers are respectively the 2nd and 5th cause of cancer mortality in France.
Surgical resection is a crucial step in the therapeutic management of colorectal cancers. For advanced ovarian cancers, the objective of cytoreductive surgery is to obtain complete macroscopic resection with no visible residual disease. One or more digestive resections are often required to achieve this goal of complete surgery (usually a modified posterior pelvic exenteration with colorectal resection).
A ligation of the inferior mesenteric artery at its origin is classically performed in left colectomies and rectal resection for colorectal cancers. This allows the resection of the colorectal segment with a complete mesocolic lymphadenectomy until the origin of the inferior mesenteric artery and a good mobilization of the descending colon to allow its anastomosis to the underlying rectal stump. This ligation of the inferior mesenteric artery at its origin is also frequently performed in cases of modified posterior pelvic exenteration for ovarian cancer.
Recently, several studies suggest that arterial ligation of the inferior mesenteric artery could be performed below the emergence of the left colic artery. Its preservation requiring a meticulous vascular dissection would allow a better vascularization of the descending colon and of the colorectal anastomosis without affecting the carcinologic quality of the resection and the number of resected lymph-nodes. Indeed, the most feared complication during colorectal anastomosis is the anastomotic leakage whose rates are on average 15% in rectal cancer with low anastomosis and 6% in ovarian cancers.
Verifying the adequate vascularization of the descending colon before performing the colorectal anastomosis is a crucial step in reducing the risk of postoperative fistula. However, quantifying this vascularization is challenging, and several techniques can be used to assess it. The gold standard technique involves measuring arterial pressure using a catheter inserted into the marginal artery of the descending colon. Other non-invasive techniques also use Doppler studies to calculate pressure in the marginal artery or assess oxygen saturation using a sterile sensor.
Studies have shown that the use of indocyanine green in colorectal surgery, particularly to evaluate perfusion before the creation of an anastomosis, significantly reduces the rate of anastomotic leakage. Indocyanine green is a fluorescent dye that, after intravenous injection, binds to plasma proteins and allows tissue perfusion to be visualized using a fluorescence system.
The objective of this project is to show that the preservation of the left colic artery is possible and allows a better vascularization of the descending colon before colorectal anastomosis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
During surgery, on the same patient who received left or colorectal resection with ligation of the lower mesenteric artery below of the emergence of the left colic artery, the steps will be as follows: * Time 1: Clamping of the inferior mesenteric artery at its origin (resulting in clamping the left colic artery), 1. Evaluation of the fluorescence intensity at the area of interest after Indocyanine green injection : 2. Measurement of the blood pressure of the marginal artery of the descending colon via pressure sensor introduced in the artery and doppler 3. Measurement of saturation via a saturation sensor 4. Measurement of systemic blood pressure using a tension cuff * Time 2: after inferior mesenteric artery release restoring arterial blood flow in the artery and at least 10min since ICG injection of time 1 to obtain its clearance. same parameters mesured
Procedure: Clamping and restauration of arterial blood of the inferior mesenteric artery
* Injection of Indocynianine green (INFRACYANINE 25mg diluted in 10 mL solvent, IV injection of 3ml at a concentration of 2.5 mg/mL or 7.5 mg), (excluding NaCl), purge 10ml NaCl, * Camera model (STORZ) * Camera/target distance: 5cm * Camera recording time (since Indocynianine green injection): 2 to 5 min with temporal identification of the injection time. Extracorporeal evaluation (by mini laparatomy extraction in colorectal surgery minimally invasive, by laparotomy in case of ovarian cancer with lights of the room switched off (laparotomy)
Measurement of the variation in vascularization of the descending colon with or without clamping of the inferior mesenteric artery quantified by the method selected during the exploratory phase of the primary endpoint.
Measurement of vascularization at the end of the descending colon with and without clamping the inferior mesenteric artery at its origin (interrupting arterial flow in the left colic artery) according to the quantification method selected in the exploratory evaluation phase. * If Indocyanine green intraveinous injection: measurement of decrease in staining time and increase in intensity * If Blood Pressure by catheter, doppler or saturation: percentage increase all the measures will define the same measure, that is to say, the vascularization of the descending colon
Time frame: During the surgery
Quantification of blood pressure in the marginal artery of the colon descending after clamping of the IMA at its origin then without clamping of the left colic artery by the other three method
Measurement of blood pressure after catheterization of the marginal artery of the descending colon. Measurement of systemic blood pressure at the same time. The measurement will be performed using an arterial catheter.
Time frame: During the surgery
Study of the anatomy of the lower mesenteric artery and its branches after arterial reconstruction of scanner performed preoperatively.
On the intraoperative Thoraco Abdomino Pelvis scanner, measure of the diameter in mm of the left colic artery.
Time frame: Before the surgery. At the baseline
Study of the anatomy of the lower mesenteric artery and its branches after arterial reconstruction of scanner performed preoperatively.
On the intraoperative Thoraco Abdomino Pelvis scanner, measure the distance in mm between the origin of the inferior mesenteric artery.
Time frame: Before the surgery. At the baseline
Study of the anatomy of the lower mesenteric artery and its branches after arterial reconstruction of scanner performed preoperatively.
On the intraoperative Thoraco Abdomino Pelvis scanner, evaluate the presence of dividing branches.
Time frame: Before the surgery. At the baseline
Evaluation of the operative parameters (operating time).
operating time : in minutes: time between opening and closing of the skin
Time frame: During the surgery
Evaluation of the operative parameters (duration of dissection of the inferior mesenteric artery).
inferior mesenteric artery dissection time : in minutes: time between the beginning of the dissection of the I and completion
Time frame: During the surgery
Evaluation of the operative parameters (duration of dissection of the left colic artery).
left colic artery dissection time : in minutes:MA time between the beginning of the artery dissection and completion
Time frame: During the surgery
Evaluation of the operative parameters (intraoperative bleeding).
intraoperative bleeding in mL: estimated total volume of blood, measured by aspiration and impregnated compresses.
Time frame: During the surgery
Evaluate postoperative parameters (within 30 days of surgery): rate of anastomotic leakage, rate of surgical recovery, duration of bowel function recovery.
Data recovery within 30 days of surgery: anastomotic leakage rate (number of patients with anastomotic leakages confirmed by scan within 30 days of surgery), surgical recovery rate (number of patients for whom a re-intervention was necessary following a postoperative complication) and duration of bowel recovery (in days, defined by the 1st gas/stool emission after the intervention, defined by a clinical assessment of the surgeon).
Time frame: 30 days after the surgery
Number of resected lymph-nodes.
Total number of lymph nodes taken from the surgical specimen analysed in anatomopathology
Time frame: 30 days after the surgery
Percentage of conservation of the colic artery.
Success Percentage of conservation of the colic artery among included patient in the study.
Time frame: 30 days after the surgery
Determine the most appropriate measurement parameter to verify and quantify the vascularization of the descending colon among the following 4 methods
* The measureof Blood pressure in the marginal artery of the colon with a pressure sensor introduced into the artery through a catheter. * Intraveinous ICG injection with the measure of duration between bolus and maximum opacification of the colon and semi-quantitative assessment of the intensity of the green. The measure will focus on the variation between the injection time and the maximum opacification (visual measurement) of the colon. * The measure of saturation in the marginal artery of the descending colon by a saturation sensor. The measure will be on the saturation variation in the artery. * The measure of BP in the marginal artery of the colon by Doppler. The measurement will be on the variation of pressure in the artery. This first phase will establish the best method to observe an increase in revascularization between clamped and non-clamped time all the measures will define the same measure, that is to say, the vascularization of the descending colon
Time frame: During the surgery for the 15 first patient
Plan to share: Yes — All data will be available after publication of the results in peer-reviewed revues, and in national and international meetings. It includes all de-identified participants' data, the study protocol, the statistical analysis plan and the clinical study report. The corresponding author will provide data and datasets generated and/or analyzed during the study upon reasonable request.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Access to study data upon written detailed request sent to ICM, from 6 months until 5 years after publication of summary data.
Access criteria: The data shared will be limit to that required for independent mandated verification of the published results, the applicant will need authorization from ICM for personal access, and data will only be transferred after signing of a data access agreement.
Started Nov 2025 (actual). Primary completion is estimated for Oct 2028, 35 months after the start.
Of 329 non-industry interventional studies with no phase under Rectal Neoplasms, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 78. This study's planned 35 months is below that.
Counting every sponsor, half of 336 studies reached it within 51 months; a quarter within 23 and three quarters within 78.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Institut du Cancer de Montpellier - Val d'Aurelle →